The Road to Remission: Treatments and Medication Safety

Treating Enthesitis-Related Arthritis (ERA) has evolved significantly in recent years. The goal is no longer just “managing pain” but achieving clinical remission—a state where there is no detectable inflammation and the child can live a completely active life ^[1][2].

The Escalation Ladder

Doctors typically follow a “stepped” approach to treatment, but the speed of this escalation depends on the severity of your child’s disease ^[3].

1. First-Line: NSAIDs: Non-steroidal anti-inflammatory drugs (like naproxen) are often used first to reduce pain and swelling ^[4]. However, if symptoms do not improve significantly within a few weeks, doctors quickly move to stronger therapies ^[3].
2. Conventional DMARDs (csDMARDs): Medications like methotrexate or sulfasalazine are used to help “calm” the immune system ^[5]. While effective for peripheral joints (like knees or ankles), these drugs are generally less effective for inflammation in the spine or sacroiliac joints ^[6][7].
3. Biologic DMARDs (bDMARDs): These are targeted therapies that block specific “chemical signals” in the immune system.
   • TNF Inhibitors: Drugs like adalimumab and etanercept block a protein called TNF-alpha ^[4]. They are the most common biologics used for ERA ^[8].
   • IL-17 Inhibitors: Secukinumab is a newer option specifically approved for ERA-JIA ^[9]. It blocks IL-17A, a key driver of inflammation in this specific subtype ^[9].

When to Go “Fast” and “Aggressive”

If your child has axial involvement (inflammation in the spine or sacroiliac joints), doctors often recommend skipping the slower conventional drugs and starting a biologic immediately ^[3]. Research shows that early, aggressive treatment is the most effective way to prevent permanent joint damage and irreversible restriction in spinal mobility later in life ^[2][10].

Medication Safety and Side Effects

While conventional and biologic DMARDs are highly effective, they work by suppressing parts of the immune system. This means your child will have a harder time fighting off everyday illnesses ^[4].

• The “Fever Rule”: If your child develops a fever (typically over 100.4°F/38°C) or shows signs of a serious infection, you will likely need to pause their biologic or DMARD medication until they recover ^[8]. Always contact your rheumatology team when your child gets sick to ask if their next dose should be held.
• Vaccine Restrictions: Children on biologic DMARDs or high-dose conventional DMARDs cannot safely receive live-attenuated vaccines ^[8]. This includes the MMR (measles, mumps, rubella), Varicella (chickenpox), and the nasal spray version of the flu vaccine. Receiving a live vaccine while on these medications can cause a severe, vaccine-induced infection. Always consult your rheumatology team before your child receives any immunizations to ensure they are safe, non-live versions.
• Routine Monitoring: Biologics and DMARDs require regular blood work to monitor liver function, kidney function, and blood cell counts ^[5]. Patients are also screened for Tuberculosis (TB) before starting a biologic, as these medications can cause dormant TB infections to become active ^[8].

Monitoring Progress: The JSpADA Index

To know if a treatment is truly working, pediatric rheumatologists use a scoring system called the Juvenile Spondyloarthritis Disease Activity (JSpADA) index ^[11][12].

This index combines several factors into one score, including:

• Active joint swelling and enthesitis (tender spots) ^[12].
• Inflammatory markers in the blood (like ESR or CRP) ^[12].
• Reports of morning stiffness ^[12].
• The patient’s own assessment of their pain ^[12].

By tracking this score over time, you and your doctor can see exactly how much progress your child is making and decide if it’s time to adjust the medication ^[13].